Abstract:Abstract Background Cystic Fibrosis (CF) is the most common, lethal autosomal-recessive disorder, and is caused by mutations in the cystic fibrosis transmembrane conductance regulator protein (CFTR), an anion channel that is found in epithelial cells lining multiple organs. The most common mutation of CFTR is deletion of phenylalanine at position 508 (CFTR-F508del), which produces a misfolded protein. This misfolded protein is confined in the endoplasmic reticulum (ER), ubiquitinated and signaled for degradation via the cytosolic proteasome. Previous studies demonstrating experimental restoration of CFTR-F508del (F508del) trafficking to the plasma membrane showed partial function of the chloride channel, raising therapeutic speculations. However, many mechanisms that underly its degradation is still unclear. Results We discovered that the E2 conjugating enzyme, UBE 2L6, aids in the degradation of F508del. We also show that UBE 2L6’s interacting E3 ligase, RNF19B, also assists in F508del degradation. We used siRNA-mediated silencing of endogenous UBE 2L6 and RNF19B in the CF human bronchial epithelial (HBE) cell line CFBE-F508del to demonstrate that there is an increase in F508del-CFTR expression. We also co-expressed UBE 2L6 and RNF 19B with F508del in HEK293 cells that demonstrated a decrease in F508del compared to control. Cycloheximide-chase (CHX) experiments using HEK 293 cells overexpressing RNF19B and F508del showed that there was a decrease in F508del half-life. Lastly, using siRNA-mediated silencing of endogenous UBE 2L6 and RNF19B in CFBE-F508del cells increased forskolin-stimulated short-circuit currents. Interestingly, there seemed to be cooperatively larger increases in short-circuit currents in CFBE-F508del cells that were silenced with UBE 2L6 or RNF19B were treated for 24 hours with VX-809. Conclusion These data suggest that there is an additional mechanism where the E2 conjugating enzyme, UBE 2L6, and the E3 ubiquitin ligase, RNF19B, is responsible for the ubiquitination and subsequent proteasomal degradation of the misfolded F508del. This study presents a novel therapeutic strategy to synergistically restore the function of F508del.

Endoplasmic Reticulum-Targeted Subunit Toxins Provide a New Approach to Rescue Misfolded Mutant Proteins and Revert Cell Models of Genetic Diseases.

Chemical and pharmacological chaperones as new therapeutic agents

Engineering and Evolution of Molecular Chaperones and Protein Disaggregases with Enhanced Activity

Pharmacological Rescue of the Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Detected by Use of a Novel Fluorescence Platform

Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR

Pharmacological Chaperones:Novel Therapeutic Strategies to Rescue Defective Protein Folding and Trafficking

Functional dissection of the retrograde Shiga toxin trafficking inhibitor Retro-2

Remodeling the endoplasmic reticulum proteostasis network restores proteostasis of pathogenic GABAA receptors

Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators

Pharmacological chaperones: a new twist on receptor folding

Ribosomal Frameshifting Selectively Modulates the Assembly, Function, and Pharmacological Rescue of a Misfolded CFTR Variant

ER-misfolded proteins become sequestered with mitochondria and impair mitochondrial function

The Mutagenic Plasticity of the Cholera Toxin B-Subunit Surface Residues: Stability and Affinity

Stabilizing Rescued Delf508 CFTR at the Plasma Membrane by Potentiation of Its Interaction with Na+/H+ Exchanger Regulatory Factor 1

ATase Inhibition Rescues Age-Associated Proteotoxicity of the Secretory Pathway.

The ER Stress Induced in Human Neuroblastoma Cells Can Be Reverted by Lumacaftor, a CFTR Corrector

Cell-based HTS identifies a chemical chaperone for preventing ER protein aggregation and proteotoxicity

Degradation of CFTR-F508del By the Ubiquitin E2 Conjugating Enzyme UBE 2L6 and the E3 Ligase RNF19B

Targeting ubiquitination machinery in cystic fibrosis: Where do we stand?

Development of the ULK1-Recruiting Chimeras (ULKRECs) to enable proximity-induced and ULK1-dependent degradation of mitochondria